AI-generated from publicly available materials.Asahi Kasei Bioprocess is set to launch its innovative VANTIJ® SU-VFC benchtop virus-filtration system at the upcoming Bioprocess International (BPI) East event in Boston. This system is tailored for laboratory-scale applications and aims to enhance automation in virus filtration processes.
The VANTIJ® SU-VFC is the inaugural benchtop model in Asahi Kasei's VANTIJ series, designed to streamline virus filtration while prioritizing user experience. It supports workflows utilizing 0.12 m² or 0.3 m² Planova 35N virus-removal filters, ensuring that essential process controls and data management capabilities are maintained for biopharmaceutical development.
Initially aimed at gene therapy manufacturing, this system addresses challenges related to production timelines, regulatory compliance, and operator training. Its user-friendly features include a guided setup layout, tool-free installation, and recipe-driven software, which collectively facilitate efficient batch reporting and key filtration processes.
The introduction of the VANTIJ® SU-VFC reflects Asahi Kasei Bioprocess's dedication to enhancing biopharmaceutical manufacturing efficiency. As the industry seeks faster pathways to deliver innovative therapies, this system represents a significant step forward in simplifying critical process steps, ultimately supporting the production of safer and more effective therapeutic products.